The Phase 1 Trial is Taking Place at the Translational Psychedelic Research Program at the University of California San Francisco VANCOUVER, BC, Nov. 2, 2021 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), an exclusively-natural psychedelic drug discovery company, announces FDA authorization to initiate the first clinical trial using naturally…


Previous articlePT269 – Adam Strauss – Comedy, OCD, and The Mushroom Cure
Next articleBraxia Scientific Graduates First Cohort of Medical Professionals from Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial